Leflunomide improves psoriasis in patients with psoriatic arthritis: An in-depth analysis of data from the TOPAS study

Dermatology

Volumn 212, Issue 3, 2006, Pages 238-249

  Nash, Peter ^a   Thaçi, Diamant ^b   Behrens, Frank ^b   Falk, Franziska ^c   Kaltwasser, J Peter ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GOETHE UNIVERSITY   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Dermatology Life Quality Index (DLQI); Leflunomide; Psoriasis; Psoriasis Area and Severity Index (PASI); Psoriatic arthritis

Indexed keywords

LEFLUNOMIDE; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; INFECTION; JAUNDICE; JOINT; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SKIN; STATISTICAL SIGNIFICANCE; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SKIN;

EID: 33645219514     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091251     Document Type: Article

References (42)

1. Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-1675.
2. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - A simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
3. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004;9:136-139.
4. Zachariae R, Zachariae C, Ibsen HH, Mortensen JT, Wulf HC: Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. Acta Derm Venereol 2004;84:205-212.
5. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284.
6. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, de la Brassinne M, Ferrandiz C, Griffiths C, Katsambas A, Kragballe K, Lynde C, Menter A, Ortonne J-P, Papp K, Prinz J, Rzany B, Ronnevig J, Saurat J-H, Stahle M, Stengel FM, van de Kerkhof P, Voorhees J: Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004;151(suppl 69):3-17.
7. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC: A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1-125.
8. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 year cohort study. J Invest Dermatol 2003;120:211-216.
9. Whiting-O'Keefe QE, Fye KH, Sack KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-716.
10. Nickoloff BJ, Wrone-Smith T: Injection of prepsoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999;155:145-158.
11. Breedveld FC, Dayer J-M: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-849.
12. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. Lancet 1999;353:259-266.
13. Strand V, Cohen S, Schiff M, Weaver A, Fleishmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-2550.
14. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-1950.
15. Liang GC, Barr WG: Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 2001;7:366-370.
16. Reich K, Hummel KM, Beckmann I, Mossner R, Neumann C: Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 2002;146:335-336.
17. Tlacuilo-Parra JA, Guevara-Gutierrez E, Rodriguez-Catellanos MA, Ornelas-Aguirre JM, Barbra-Gomez JF, Salazar-Paramo M: Leflunomide in the treatment of psoriasis: results of a phase II open trial. Br J Dermatol 2004;150:970-976.
18. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-2020.
19. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice (Topic E6). 1996. http://www.ich.org/MediaServer.jser?@_ID=482&@_MODE=GLB.
20. Fredriksson T, Pettersson U: Severe psoriasis - Oral therapy with a new retinoid. Dermatologica 1978;157:238-244.
21. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
22. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordan KB, Zitnik R: A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-1632.
23. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-542.
24. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE: An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-727.
25. Chew AL, Bennett A, Smith CH, Barker J, Kirham B: Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004;151:492-496.
26. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-3080.
27. Marcil I, Stern RS: Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358:1042-1045.
28. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG: A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-866.
29. Sampogna F, Sera F, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators: Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602-607.
30. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ: Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997;24:511-517.
31. Walters SJ, Brazier JE: What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003;1:4-12.
32. Ware JE Jr: SF-36 health survey update. Spine 2000;25:3130-3139.
33. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA: Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcome 2003;1:53-62.
34. de Korte J, Sprangers MAG, Mombers FMC, Bos JD: Quality of life in patients with psoriasis: a systematic literature review. J Invest Dermatol Symp Proc 2004;9:140-147.
35. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR: Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12-25.
36. Ollendorf DA, Peterson AN, Doyle J, Huse DM: Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. Am J Manag Care 2002;8(suppl):S203-213.
37. Kalden JR, Schattenkirchner M, Sörensen H, Emery P, Deighton C, Rozman B, Breedveld F: The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up study. Arthritis Rheum 2003;48:1513-1520.
38. Cannon GW, Holden W, Juhaeri J, Dai W, Scarazzini L, Stang P: Adverse events with disease modifying anti-rheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. Arthritis Rheum 2004;31:1906-1911.
39. Fischer TW, Bauer HHI, Graefe T, Barta U, Eisner P: Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology 2003;207:386-389.
40. Rivarola de Gutierrez E, Abaca H: Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy. Dermatology 2004;208:232-233.
41. Marguerie L, Flip RM, Grardel B, Beaurain D, Duquesnoy B, Delcambre B: Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine 2002;69:275-281.
42. Kyle S, Chandler D, Griffiths CEM, Helliwell P, Lewis J, McInnes I, Oliver S, Symmons D, McHugh N, on behalf of the British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG): Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology 2005;44:390-397.